Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Restoring airway surface liquid in cystic fibrosis.

Ratjen F.

N Engl J Med. 2006 Jan 19;354(3):291-3. No abstract available.

PMID:
16421371
2.

Altering airway surface liquid volume: inhalation therapy with amiloride and hyperosmotic agents.

Hirsh AJ.

Adv Drug Deliv Rev. 2002 Dec 5;54(11):1445-62. Review.

PMID:
12458154
3.

Osmolytes and ion transport modulators: new strategies for airway surface rehydration.

Goralski JL, Boucher RC, Button B.

Curr Opin Pharmacol. 2010 Jun;10(3):294-9. doi: 10.1016/j.coph.2010.04.003. Epub 2010 May 1. Review.

PMID:
20439165
4.

Inhaled hypertonic saline as a therapy for cystic fibrosis.

Elkins MR, Bye PT.

Curr Opin Pulm Med. 2006 Nov;12(6):445-52. Review.

PMID:
17053496
5.

[Inhaled therapies for cystic fibrosis].

Lahzami S, Nicod LP.

Rev Med Suisse. 2011 Nov 23;7(318):2285-8. Review. French.

PMID:
22400363
6.

The expanding armamentarium of drugs to aid sputum clearance: how should they be used to optimize care?

Bilton D, Stanford G.

Curr Opin Pulm Med. 2014 Nov;20(6):601-6. doi: 10.1097/MCP.0000000000000104. Review.

PMID:
25221855
7.

Hypertonic saline in treatment of pulmonary disease in cystic fibrosis.

Reeves EP, Molloy K, Pohl K, McElvaney NG.

ScientificWorldJournal. 2012;2012:465230. doi: 10.1100/2012/465230. Epub 2012 May 3. Review.

8.

Inhaled mannitol for the treatment of cystic fibrosis.

Hurt K, Bilton D.

Expert Rev Respir Med. 2012 Feb;6(1):19-26. doi: 10.1586/ers.11.87. Review.

PMID:
22283575
9.

Hypertonic saline treatment of cystic fibrosis.

Taylor LM, Kuhn RJ.

Ann Pharmacother. 2007 Mar;41(3):481-4. Epub 2007 Feb 27. Review.

PMID:
17327291
10.

The epithelium as a target for therapy in cystic fibrosis.

Thelin WR, Boucher RC.

Curr Opin Pharmacol. 2007 Jun;7(3):290-5. Epub 2007 May 1. Review.

PMID:
17475561
11.

Rationale for hypertonic saline therapy for cystic fibrosis lung disease.

Tarran R, Donaldson S, Boucher RC.

Semin Respir Crit Care Med. 2007 Jun;28(3):295-302. Review.

PMID:
17562499
12.

Airway-rehydrating agents for the treatment of cystic fibrosis: past, present, and future.

Pettit RS, Johnson CE.

Ann Pharmacother. 2011 Jan;45(1):49-59. doi: 10.1345/aph.1P428. Epub 2010 Dec 14. Review.

PMID:
21156814
13.

Inhaled mannitol in cystic fibrosis.

Wills PJ.

Expert Opin Investig Drugs. 2007 Jul;16(7):1121-6. Review.

PMID:
17594195
14.

Pharmacologic agents for mucus clearance in bronchiectasis.

Nair GB, Ilowite JS.

Clin Chest Med. 2012 Jun;33(2):363-70. doi: 10.1016/j.ccm.2012.02.008. Epub 2012 Apr 6. Review.

PMID:
22640851
15.

Pharmacotherapy of impaired mucociliary clearance in non-CF pediatric lung disease. A review of the literature.

Boogaard R, de Jongste JC, Merkus PJ.

Pediatr Pulmonol. 2007 Nov;42(11):989-1001. Review.

PMID:
17902149
16.

Regulation of human airway surface liquid.

Widdicombe JH, Widdicombe JG.

Respir Physiol. 1995 Jan;99(1):3-12. Review.

PMID:
7740210
17.

Other medications for aerosol delivery.

Rubin BK.

Paediatr Respir Rev. 2006;7 Suppl 1:S76-9. Epub 2006 Jun 5. Review.

PMID:
16798603
18.

Inhaled interventions in cystic fibrosis: mucoactive and antibiotic therapies.

Hurt K, Bilton D.

Respiration. 2014;88(6):441-8. doi: 10.1159/000369533. Epub 2014 Nov 28. Review.

19.

Osmotic stimuli increase clearance of mucus in patients with mucociliary dysfunction.

Daviskas E, Robinson M, Anderson SD, Bye PT.

J Aerosol Med. 2002 Fall;15(3):331-41. Review.

PMID:
12396422
20.

Mucus structure and properties in cystic fibrosis.

Rubin BK.

Paediatr Respir Rev. 2007 Mar;8(1):4-7. Epub 2007 Mar 21. Review.

PMID:
17419972

Supplemental Content

Support Center